Clinical trials
Multiple myeloma clinical trials
A cancer of plasma cells in the bone marrow that affects the blood and bones. We’re tracking 540 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06115135RecruitingPhase 2
Venetoclax with isatuximab and dexamethasone for myeloma
This trial tests a combination of three drugs (venetoclax, isatuximab, and dexamethasone) for people with multiple myeloma that has come back or stopped responding to earlier treatments. It is for patients whose cancer cells have a specific genetic change, called t(11;14).
West Hollywood, CaliforniaAges Any age - NCT07477912RecruitingPhase 1/Phase 2
BCMA-targeting CAR-T for relapsed/refractory multiple myeloma
This trial tests a new kind of immunotherapy called CAR-T that targets BCMA on myeloma cells. It is for people whose multiple myeloma has come back after or not responded to at least two previous treatments.
MinskAges 18 years+ - NCT07477587RecruitingPhase 1
Comparing two myeloma treatments for new patients
This trial tests a new drug combination (HLX15-SC) against an approved treatment (DARZALEX FASPRO) along with lenalidomide and dexamethasone for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant.
Springdale, ArkansasAges 18 years+ - NCT07479979RecruitingPhase 1/Phase 2
Study of selinexor with carfilzomib, isatuximab and dexamethasone for relapsed/refractory multiple myeloma
This trial tests a combination of four drugs (selinexor, carfilzomib, isatuximab, and dexamethasone) in patients whose multiple myeloma has come back or stopped responding to prior treatment. The goal is to see if this combination can shrink the cancer and help patients whose disease has high-risk features, like certain chromosome changes.
Madison, WisconsinAges 18 years+ - NCT07463807RecruitingPhase 1/Phase 2
Comparing two drug combinations for multiple myeloma that returned quickly
This study tests a new combination of two drugs, teclistamab and pomalidomide, against the usual treatment of three drugs for multiple myeloma that has come back shortly after a standard treatment. The goal is to see if the new combination works better or is safer.
Duarte, CaliforniaAges 18 years+ - NCT07454382RecruitingPhase 2
Study of elranatamab and cyclophosphamide for multiple myeloma
This trial studies a new medicine called elranatamab combined with the chemotherapy drug cyclophosphamide for people with multiple myeloma that has returned or not responded to prior treatments. It may be a good option if you have aggressive or high-risk myeloma.
Basking Ridge, New JerseyAges 18 years+ - NCT07456605RecruitingPhase 1
Testing liposomal curcumin for multiple myeloma
This trial tests a special form of curcumin (the ingredient in turmeric) wrapped in tiny fat particles to see if it's safe and helpful for people with multiple myeloma that has come back or not responded to other treatments. It may offer an option when standard therapies are no longer effective.
Toronto, OntarioAges 18 years+ - NCT07446777Recruiting
Fasting and Mediterranean diet for multiple myeloma
This study tests whether a special diet—longer nightly fasting plus a Mediterranean eating pattern—can help people with multiple myeloma or its early stages. If you qualify, you will be randomly assigned to start the diet right away or join a waitlist group.
Miami, FloridaAges 18 years+ - NCT07452198RecruitingPhase 3
Study of new drug for relapsed or hard-to-treat multiple myeloma
This trial tests a new medicine (GR1803) against a standard combination treatment for people whose multiple myeloma has come back or stopped responding to prior therapies. It aims to see if the new drug works better.
TianjinAges 18 years+ - NCT07429721RecruitingEarly Phase 1
Testing QI-019A for multiple myeloma that came back
This trial tests a new drug called QI-019A for people whose multiple myeloma has returned or stopped responding to at least two prior treatments. The goal is to see if it is safe and if it can help control the disease.
Wuhan, HubeiAges 18 years+ - NCT07409454RecruitingPhase 2
Post-transplant treatment for multiple myeloma with a bispecific antibody
This trial tests a drug that helps your immune system target and kill myeloma cells after a stem cell transplant. It is for people with newly diagnosed multiple myeloma who still have minimal residual disease (small amounts of cancer) after their first transplant.
TianjinAges 18 years+ - NCT06158412RecruitingPhase 2
ATRA plus KPD for relapsed or refractory multiple myeloma
This trial tests a combination of all-trans retinoic acid (a form of vitamin A) with a chemotherapy regimen called KPD for patients whose multiple myeloma has come back or is not responding to standard treatments. The goal is to see if this combination can help control the disease.
Xiamen, FujianAges 18 years+ - NCT07382739RecruitingPhase 2
Radiation and immunotherapy for advanced multiple myeloma
This trial tests whether combining radiation therapy with the drug elranatamab can help people with multiple myeloma that has come back or not responded to treatment, especially when the cancer has spread to soft tissues or bones outside the bone marrow. The goal is to see if this combination can make the immune system fight the cancer more effectively.
Houston, TexasAges Any age - NCT07376733Recruiting
Breathing exercises for heart and lung health in multiple myeloma
This study looks at whether simple, guided breathing exercises can improve heart and lung health in people with multiple myeloma. It may help you feel stronger and manage side effects during treatment.
MadridAges 18 years+ - NCT07377435RecruitingPhase 1
Vaccine after CAR-T therapy for multiple myeloma
This trial tests whether a personalized vaccine (DC/MM fusion) given after standard CAR-T cell therapy can help prevent the cancer from coming back. It is for people with multiple myeloma that has returned or not responded to treatment.
Boston, MassachusettsAges 18 years+ - NCT04271644RecruitingPhase 1/Phase 2
CAR-T treatment targeting BCMA for hard-to-treat myeloma
This Phase 1/2 study tests a BCMA-targeting CAR-T cell therapy for people with relapsed or refractory multiple myeloma or related plasma cell diseases. It may help by using your own immune cells, engineered to recognize a specific target on cancer cells.
Kunming, YunnanAges 18–75 - NCT04776330RecruitingPhase 1/Phase 2
BCMA-targeted CAR-T for relapsed or refractory multiple myeloma
This trial tests a lab-made immune cell therapy (CAR-T) designed to attack a protein called BCMA on myeloma cells. It’s for adults whose multiple myeloma or related plasma cell disease has come back or didn’t respond to prior treatment, aiming to improve cancer control.
Kunming, YunnanAges 18–75 - NCT06846905Recruiting
Cost and effects of raising the dose of myeloma drugs at home vs. hospital
This study compares whether raising the dose of your current bispecific antibody is more cost-effective when done as an outpatient (day hospital) or as an inpatient. It aims to find the best way to manage your treatment safely.
ToulouseAges 18 years+ - NCT07336823RecruitingEarly Phase 1
JY232 CAR-T cell therapy for relapsed multiple myeloma
This trial tests an investigational CAR-T cell therapy called JY232 for people with multiple myeloma that has returned or not responded to at least two prior treatments. The therapy targets a protein called BCMA on myeloma cells to help your immune system fight the cancer.
Foshan, GuangdongAges 18–75 - NCT07336472RecruitingPhase 1/Phase 2
IBI3003 for relapsed or refractory multiple myeloma
This trial tests a new drug called IBI3003 for people with multiple myeloma that has come back or not responded to at least 3 prior treatments. The goal is to see if IBI3003 is safe and effective.
Scottsdale, ArizonaAges 18 years+ - NCT07319897RecruitingPhase 2/Phase 3
BCMA PET scan for multiple myeloma imaging
This trial tests a new type of PET scan that uses a radioactive tracer (68Ga-BCMA) to find active multiple myeloma cells in your body. It may help doctors better detect and monitor the disease.
Beijing, Beijing MunicipalityAges 18–80 - NCT07312942Recruiting
Breathing and exercise for multiple myeloma patients
This trial tests whether adding slow, controlled breathing exercises to a supervised exercise program can improve your quality of life and physical function while you are on daratumumab treatment for multiple myeloma.
MadridAges 18 years+ - NCT07294625RecruitingEarly Phase 1
Gene therapy for relapsed/refractory multiple myeloma
This trial tests a new gene therapy, LVIVO-TaVec200, for people with multiple myeloma that has returned or not responded to other treatments. The goal is to see if it can help control the cancer.
Zhengzhou, HenanAges 18 years+ - NCT07284758RecruitingPhase 2
Cemsidomide and dexamethasone for relapsed/refractory multiple myeloma
This clinical trial tests a new combination of two medicines (cemsidomide and dexamethasone) for people with multiple myeloma that has come back or stopped responding after at least three prior treatments. The goal is to see if this new drug can help control the cancer when other options have stopped working.
Huntsville, AlabamaAges 18 years+
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for multiple myeloma?
- Yes. Clin2 currently lists 540 recruiting multiple myeloma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a multiple myeloma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a multiple myeloma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.